Skip to main content
SpringerLink
Log in

AR-V7 als prädiktiver Biomarker für das Prostatakarzinom – „more than just prophecy?“

AR-V7 as a predictive biomarker for prostate cancer—more than just prophecy

  • Journal Club
  • Published:
Der Urologe Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Antonarakis ES, Lu C, Luber B et al (2015) Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2015.1341

    Article  PubMed  PubMed Central  Google Scholar 

  2. Antonarakis ES, Lu C, Luber B et al (2017) Clinical significance of androgen receptor splice variant‑7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide. J Clin Oncol. https://doi.org/10.1200/JCO.2016.70.1961

    Article  PubMed  PubMed Central  Google Scholar 

  3. Antonarakis ES, Lu C, Wang H et al (2014) AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371:1028–1038. https://doi.org/10.1056/NEJMoa1315815

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Armstrong AJ, Halabi S, Luo J et al (2019) Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study. J Clin Oncol 37:1120–1129. https://doi.org/10.1200/JCO.18.01731

    Article  CAS  PubMed  Google Scholar 

  5. Bernemann C, Steinestel J, Humberg V et al (2018) Performance comparison of two androgen receptor splice variant 7 (AR-V7) detection methods. BJU Int 122:219–226. https://doi.org/10.1111/bju.14146

    Article  CAS  PubMed  Google Scholar 

  6. de Wit R, de Bono J, Sternberg CN et al (2019) Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med. https://doi.org/10.1056/NEJMoa1911206

    Article  PubMed  Google Scholar 

  7. Lu J, Van der Steen T, Tindall DJ (2015) Are androgen receptor variants a substitute for the full-length receptor? Nat Rev Urol 12:137–144. https://doi.org/10.1038/nrurol.2015.13

    Article  CAS  PubMed  Google Scholar 

  8. Onstenk W, Onstenk W, Sieuwerts AM et al (2015) Efficacy of cabazitaxel in castration-resistant prostate cancer is independent of the presence of AR-V7 in circulating tumor cells. Eur Urol. https://doi.org/10.1016/j.eururo.2015.07.007

    Article  PubMed  Google Scholar 

  9. Scher HI, Lu D, Schreiber NA et al (2016) Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2016.1828

    Article  PubMed  PubMed Central  Google Scholar 

  10. Sharp A, Coleman I, Yuan W et al (2019) Androgen receptor splice variant‑7 expression emerges with castration resistance in prostate cancer. J Clin Invest 129:192–208. https://doi.org/10.1172/JCI122819

    Article  PubMed  Google Scholar 

  11. Sharp A, Welti JC, Lambros MBK et al (2019) Clinical utility of circulating tumour cell androgen receptor splice variant‑7 status in metastatic castration-resistant prostate cancer. Eur Urol 76:1–10. https://doi.org/10.1016/j.eururo.2019.04.006

    Article  CAS  Google Scholar 

  12. Steinestel J, Bernemann C, Schrader AJ, Lennerz JK (2017) Re: Emmanuel S. Antonarakis, Changxue Lu, Brandon Luber, et al. Clinical significance of androgen receptor splice variant‑7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide. J Clin Oncol 2017;35:2149–56: aR-V7 testing: what’s in it for the patient? Eur Urol. https://doi.org/10.1016/j.eururo.2017.06.031

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Urologie und Kinderurologie, Universitätsklinikum Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Deutschland

    C. Bernemann &  L.-M. Krabbe

Authors
  1. C. Bernemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L.-M. Krabbe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L.-M. Krabbe.

Ethics declarations

Interessenkonflikt

C. Bernemann und L.-M. Krabbe geben an, dass kein Interessenkonflikt besteht.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bernemann, C., Krabbe, LM. AR-V7 als prädiktiver Biomarker für das Prostatakarzinom – „more than just prophecy?“. Urologe 59, 80–83 (2020). https://doi.org/10.1007/s00120-019-01086-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-019-01086-8

Search

Navigation